Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2005
12/22/2005WO2005120552A1 METHODS AND FORMULATIONS OF GnRH/LEUKOTOXIN CHIMERAS FOR TESTOSTERONE SUPPRESSION
12/22/2005WO2005120551A1 Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
12/22/2005WO2005120550A2 A method for altering the cd4/cd8 ratio and the mononuclear cellular infiltrate into a tumor
12/22/2005WO2005120549A2 Local delivery of growth factors for stem cell transplantation
12/22/2005WO2005120548A1 Method of treating parkinson’s disease in humans by direct infusion of glial cell-line derived neurotrophic factor into the zona incerta
12/22/2005WO2005120547A1 Use of neuregulin-3 for inducing mammary cell differentiation and for the treatment of breast cancer
12/22/2005WO2005120546A2 Compositions and methods for topical diagnostic and therapeutic transport
12/22/2005WO2005120545A1 Compositions and methods for treatment of cardiovascular disease
12/22/2005WO2005120544A1 Enzymatic treatment of retinitis pigmentosa and relevant pharmaceutical composition therefor in form of a kit
12/22/2005WO2005120543A1 Compositions containing d-carnosine
12/22/2005WO2005120542A2 Methods of treating disease with random copolymers
12/22/2005WO2005120541A1 Process for producing protein having its antihypertensive activity enhanced
12/22/2005WO2005120540A2 Interferon alpha or beta for treatment of cardiomyopathy and endothelial dysfunction
12/22/2005WO2005120539A2 Novel use of peptide compounds for treating pain in trigeminal neuralgia
12/22/2005WO2005120514A1 Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
12/22/2005WO2005120479A1 Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
12/22/2005WO2005120475A2 Pharmaceutical composition for the treatment of bacterial infections and sepsis
12/22/2005WO2005120474A2 Phophodiesterase 10a inhibitors to amplify the action of glp1-mimetics or dpp-iv inhibitors in diabetes
12/22/2005WO2005120467A2 Dosage form containing the active ingredient cholylsarcosine
12/22/2005WO2005120464A1 Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
12/22/2005WO2005120457A1 Immune enhancing compositions and methods of use thereof
12/22/2005WO2005120453A1 Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons
12/22/2005WO2005120222A2 Genetically modified non-human mammals and cells
12/22/2005WO2005110454A8 Protective binding members of pyy for the treatment of metabolic disorders
12/22/2005WO2005107767A3 Modulation of lysophosphatidylcholine and treatment of diet-induced conditions
12/22/2005WO2005104763A3 Improved method for identifying peptides in a biological sample
12/22/2005WO2005103080A3 Stable oxidation resistant powdered hemoglobin, methods of preparing same, and uses thereof
12/22/2005WO2005100382B1 Vertebrate peptide modulators of lipid metabolism
12/22/2005WO2005097814A3 Composition and method for inhibiting platelet aggregation
12/22/2005WO2005094533A3 Trail-r as a negative regulator of innate immune cell responses
12/22/2005WO2005082399A3 Treatment of bacterial infections
12/22/2005WO2005082023A3 Heterocyclic self-immolative linkers and conjugates
12/22/2005WO2005079828A3 Treatment of abnormalities of the first metatarsophalangeal joint of the foot
12/22/2005WO2005074972A3 Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists
12/22/2005WO2005074645A3 Methods and compositions for modulating angiogenesis
12/22/2005WO2005061537A3 Squamous cell carcinoma antigens and use thereof
12/22/2005WO2005051321A3 Treatment of inflammatory bowel disease through induction of indoleamine 2,3-dioxygenase
12/22/2005WO2005051289A3 Homogeneous preparations of chimeric proteins
12/22/2005WO2005047326A3 Interleukin-10 antibodies
12/22/2005WO2005046569A3 Pharmaceutical compositions for the treatment of sars
12/22/2005WO2005037855A3 T cell epitopes useful in a yersinia pestis vaccine and as diagnostic tools and methods for identifying same
12/22/2005WO2005034737A3 Methods for diagnosing and treating endoplasmic reticulum (er) stress diseases
12/22/2005WO2005023290A3 Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
12/22/2005WO2005019241A3 Cationic antimicrobial peptides and compositions thereof
12/22/2005WO2005014811A3 RNA INTERFERENCE MEDIATED INHIBITION OF XIAP GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
12/22/2005WO2004111074A3 In vivo production of a clostridial neurotoxin light chain peptide
12/22/2005WO2004110389A3 Sigma ligands for neuronal regeneration and functional recovery
12/22/2005WO2004105789A8 Grf analog compositions and their use
12/22/2005WO2004096133A3 Method for inhibiting cellular activation by insulin-like growth factor-1
12/22/2005WO2004093823A3 Polyethelene glycol link glp-1 compounds
12/22/2005WO2004085621A3 Gene expression in breast cancer
12/22/2005WO2004072241A3 Compositions and methods for cleaving iap
12/22/2005WO2004035535A3 Erythrocyte differentiation factor, gene encoding same, and methods of use thereof
12/22/2005WO2004020610A3 Methods and compositions for modulating xbp-1 activity
12/22/2005WO2004005483A3 ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
12/22/2005WO2003092611A3 Methods of inducing formation of functional and organized lymphatic vessels
12/22/2005WO2003057856A3 Dominant negative proteins and methods thereof
12/22/2005WO2003049687A3 Medicinal compositions & therapeutic methods
12/22/2005WO2002083874A3 Endothelial cell expression patterns
12/22/2005US20050283842 Mipp1 homologous nucleic acids and proteins involved in the regulation of energy homeostatis
12/22/2005US20050283045 Capsule medical instrument with oxygen generator
12/22/2005US20050282999 Beta-amyloid peptide-binding proteins and polynucleotides encoding the same
12/22/2005US20050282882 Diamines as modulators of chemokine receptor activity
12/22/2005US20050282855 Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
12/22/2005US20050282794 Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
12/22/2005US20050282771 treating bleeding disorder selected from a chronic or acute bleeding disorder, a congenital coagulation disorder caused by a blood factor deficiency, and an acquired coagulation disorder, by administering a composition comprising a procoagulant amount of a fucoidan
12/22/2005US20050282766 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
12/22/2005US20050282762 Antisense oligonucleotides for treating atopic diseases and neoplastic cell proliferation
12/22/2005US20050282760 Antisense modulation of ptpn12 expression
12/22/2005US20050282757 Peptide boronic acid compounds useful in anticoagulation
12/22/2005US20050282756 Oral delivery of peptide pharmaceutical compositions
12/22/2005US20050282755 Compositions having antimicrobial activity and uses thereof
12/22/2005US20050282754 Peptides that mimic human hemochromatosis protein function that lowers the binding affinity of transferrin receptor for transferrin to reduce iron uptake and/or accumulation by a cell and nucleic acids encoding them
12/22/2005US20050282753 Bacteriocins and novel bacterial strains
12/22/2005US20050282752 IL-1ra variants
12/22/2005US20050282751 Therapeutic agent for renal anemia
12/22/2005US20050282750 reducing, prevention, reverse cholesterol transportation; supplying apolipoprotein
12/22/2005US20050282749 Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
12/22/2005US20050282748 Glue compositions for lung volume reduction
12/22/2005US20050282747 Methods and compositions for wound healing
12/22/2005US20050282745 Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
12/22/2005US20050282744 MUC1 cytoplasmic tail peptide; inducing an immune response to MUC1-expressing tumor cells
12/22/2005US20050282743 Molecular interactions in cells
12/22/2005US20050282742 Such as bortezomib, by freeze drying
12/22/2005US20050282741 Peptides and their use to ameliorate cell death
12/22/2005US20050282740 Methods and compositions for regulating protein-protein interactions
12/22/2005US20050282739 Metallopeptide compounds
12/22/2005US20050282738 Alpha 1-acid glycoprotein, alpha 2-HS glycoprotein, alpha 1-antitrypsin, and fragments thereof induce apoptosis in cancer cell lines
12/22/2005US20050282737 Procollagen (III) propeptides and related substances for treating fibrotic diseases
12/22/2005US20050282736 ligating recombinant intein domains to a linear synthetic protein to form a compound D1-X(n)-D2, where D1 and D2 are catalytic domains of an intein and X is a protein; cell-free; producing small cyclic peptides containing non-genetically encodable amino acids; for drugs
12/22/2005US20050282735 Von Willebrand Factor (VWF); prevents a bleeding diathesis and reduces pre-, peri- and postoperative blood loss in acquired Von Willebrand syndromes such as in cardiovascular diseases requiring surgical procedures
12/22/2005US20050282733 Differentiation modulating agents and uses therefor
12/22/2005US20050282731 Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
12/22/2005US20050282729 Cysteine-rich secretory protein (CRISP); CRISP polypeptide inhibits tyrosine phosphorylation of sperm proteins; inhibiting sperm fertilizing-ability without affecting the hormonal balance in male or females
12/22/2005US20050282280 Oncolytic adenoviral vectors encoding GM-CSF
12/22/2005US20050282277 Methods of increasing platelet and hematopoietic stem cell production
12/22/2005US20050282255 Cell growth differentiation factor (MP52) for use in treatment and prevention of nervous system, dental, skin, connective tissue and bone disorders; wound healing agents
12/22/2005US20050282253 Inhibit endothelial cell proliferation, angiogenesis and cause tumor regression; antiproliferative, anticarcinogenic and antitumor agents
12/22/2005US20050282251 Heparanase II, a novel human heparanase paralog
12/22/2005US20050282240 Method for identifying peptides in a biological sample
1 ... 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 ... 3163